Can-Fite BioPharma Ltd. filings document foreign-private-issuer disclosures for a clinical-stage biotechnology company whose American Depositary Shares trade under CANF. Its Form 6-K reports furnish press releases, annual and special meeting materials, proxy statements, voting instruction cards for ADS holders, and shareholder-vote results.
The company’s regulatory record covers clinical and regulatory updates for A3AR drug candidates, Namodenoson and Piclidenoson patent matters, partner-related development disclosures, operating and financial results, capital-structure items, registration-statement incorporation for Form S-8 and Form F-3 filings, governance matters, and risks connected to drug development and public-company financing.
Can-Fite Biopharma Ltd. is updating its Form F-1 registration (Registration No. 333-288890) via a prospectus supplement dated March 5, 2026 to cover up to 1,250,000 American Depositary Shares (representing 2,500,000 ordinary shares) and related warrants and pre-funded warrants.
The supplement incorporates a Form 6-K describing an inducement arrangement: a holder agreed to exercise 795,869 Existing Warrants for cash at a reduced price of $5.00 per ADS, yielding approximately $4.0 million gross proceeds, and the Company will issue New Warrants to purchase 1,591,738 ADSs at $5.00. The Company engaged H.C. Wainwright as placement agent with a 7.0% cash fee, a 1.0% management fee and Placement Agent Warrants to purchase 55,711 ADSs at an exercise price of $6.25. The closing was expected on or about March 5, 2026, and the Company agreed to file a resale registration statement and use commercially reasonable efforts to have it declared effective within 90 days.
Can-Fite BioPharma Ltd. entered a definitive inducement agreement leading to the immediate cash exercise of warrants to purchase 795,869 ADSs at a reduced exercise price of $5.00 per ADS, generating expected gross proceeds of approximately $4.0 million before fees.
In return, the investor will receive new unregistered warrants to purchase up to 1,591,738 ADSs at $5.00 per ADS, exercisable until two years after the effectiveness of a resale registration statement. H.C. Wainwright & Co. will receive fees, expense reimbursements and warrants for 55,711 ADSs. Can-Fite plans to use net proceeds for research and development, clinical trials, and general corporate purposes.
Can-Fite BioPharma Ltd. reported that its drug candidate namodenoson successfully met the primary endpoint of safety in a Phase 2a study for advanced pancreatic ductal adenocarcinoma. In this open-label trial, 20 heavily pretreated patients received namodenoson, and the treatment was described as very well tolerated with no new safety signals.
The safety profile in pancreatic cancer was consistent with prior experience in other oncological indications. Secondary endpoints include overall survival and progression-free survival; survival follow-up is ongoing, with about one-third of patients alive at the data cut-off. Namodenoson, a selective A3 adenosine receptor agonist, has Orphan Drug Designation from the U.S. FDA for pancreatic cancer and is also being studied in liver cancer and MASH.
Can-Fite BioPharma Ltd. held a Special General Meeting of Shareholders on March 3, 2026, but it was adjourned for one week because there were not enough shareholders present to form a quorum. The Meeting is now scheduled to reconvene on March 10, 2026 at 3:00 p.m., Israel time.
The reconvened Meeting will take place at the Company’s offices at 26 Ben Gurion Street, Ramat Gan, Israel. This update simply informs shareholders of the new date, time and place so they can attend and participate in the Meeting.
Can-Fite BioPharma filed a 6-K describing a new peer-reviewed publication showing an anti-obesity effect of its lead drug candidate, namodenoson. In cell and high-fat diet mouse models, namodenoson reduced adipocyte proliferation, lipid accumulation, and weight gain, while modulating metabolic and inflammatory pathways such as adiponectin, PI3K, NF-κB, Akt, and Wnt/β-catenin.
The findings align with earlier Phase IIa data in MASH patients, where three months of treatment was associated with reduced liver fat and body weight, and support further evaluation of namodenoson as a potential oral obesity treatment. Namodenoson is already in Phase III for advanced liver cancer and Phase IIb for MASH, and the company notes obesity as a rapidly growing market projected to reach $60.5 billion by 2030.
Can-Fite BioPharma Ltd. reports that the Canadian Patent Office has issued a notice of allowance for a patent covering its oral drug Namodenoson as an anti-obesity therapy. The patent protects the use of this A3 adenosine receptor agonist to reduce fat mass and body weight in Canada.
The patent stems from data showing Namodenoson increased adiponectin, a hormone that regulates fat production, reduced body weight in an obesity animal model, and produced a 2.3% weight loss over three months in a MASH Phase IIa study. Can-Fite already holds similar Namodenoson obesity patents in the United States and Australia.
Namodenoson is also in Phase III for advanced liver cancer, Phase IIb for MASH, and Phase IIa for pancreatic cancer, and has shown an excellent oral safety profile across multiple clinical studies. Can-Fite highlights that expanding intellectual property into metabolic indications like fat loss may support future development and partnering, within a global obesity treatment market projected to reach $60.5 billion by 2030 with a ~22% CAGR.
Can-Fite BioPharma reports a single compassionate-use case in which its liver drug candidate Namodenoson helped clinically stabilize a patient with advanced decompensated cirrhosis until a compatible donor became available, enabling a successful liver transplantation. Physicians describe this as an encouraging observation but stress that individual cases must be interpreted with caution.
Namodenoson is an orally bioavailable A3 adenosine receptor agonist with anti-inflammatory and anti-fibrotic properties and a favourable safety profile in prior studies. It is being tested in a pivotal Phase III trial for advanced liver cancer, a Phase IIb trial for MASH, and a Phase IIa study in pancreatic cancer. Can-Fite also highlights its broader pipeline, including Piclidenoson for psoriasis and CF602 for erectile dysfunction.
Can-Fite BioPharma Ltd. reports that it received a notice of non-compliance from NYSE American because its audit committee currently has fewer than three independent members following an independent director’s resignation. The company has until the earlier of its next annual shareholder meeting or January 14, 2027 (or, if that meeting is held before July 13, 2026, until July 13, 2026) to regain compliance, and its ADSs continue to trade on NYSE American under the symbol CANF.
To address this, Can-Fite has called a Special General Meeting for March 3, 2026 in Ramat Gan, Israel. Shareholders and ADS holders of record as of February 5, 2026 will vote on electing Ilan Tamir as an external director, with the expectation that he will join the audit committee, helping restore compliance. They will also vote on granting each non-executive director (excluding the executive chair) 16,000 options at an exercise price of NIS 6.767 per ordinary share under the 2023 Share Option Plan and on adopting a renewed compensation policy that updates salary ranges, benefits, equity incentives and a detailed clawback framework for incentive-based pay.
Can-Fite reports 2,618,424 ordinary shares outstanding as of January 26, 2026, each carrying one vote at the meeting, with specific quorum and majority rules, including special approval thresholds for certain pay-related items involving controlling or interested shareholders.
Can-Fite BioPharma Ltd. reports a clinical milestone, completing patient enrollment in its Phase 2a pancreatic cancer study of its liver drug Namodenoson. The multicenter, open-label trial includes patients with advanced pancreatic adenocarcinoma whose disease has progressed after at least one prior therapy and is focused primarily on safety, with additional evaluation of clinical activity and pharmacokinetics.
Patients receive 25 mg oral Namodenoson twice daily in continuous 28‑day cycles, and the company states that Namodenoson has shown a favorable safety profile to date, indicating the primary safety endpoint has been demonstrated so far. Can-Fite expects top-line efficacy data from this study in Q3 2026. Namodenoson, a selective A3 adenosine receptor agonist, holds FDA Orphan Drug Designation for pancreatic cancer and is also in Phase 3 and Phase 2 trials for other liver indications.
Can-Fite Biopharma Ltd. filed a Form 6-K reporting that board member Yaacov Goldman resigned from its Board of Directors and all board committees, effective immediately on January 14, 2026. The company states that Mr. Goldman resigned for personal reasons and that his departure was not due to any disagreement with the company regarding its operations, policies, or practices. The report is also incorporated by reference into Can-Fite’s existing registration statements on Form S-8 and Form F-3, meaning those registration statements now include this update.